Gomari et al. fused a HER2 targeting DARPins (designed ankyrin repeat proteins) to Lamp2b for targeting HER2 positive breast cancers which resulted in fourfold uptake of engineered exosomes to HER2 positive BT-474 breast cancer cells in vitro [113]. The gene discussed is ERBB2; the disease is breast carcinoma.